Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $21.40.

STOK has been the subject of a number of analyst reports. Wedbush restated an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Thursday, August 8th.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the sale, the insider now owns 2,485 shares of the company’s stock, valued at $34,168.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. bought a new stake in shares of Stoke Therapeutics in the second quarter worth $19,835,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Stoke Therapeutics in the first quarter worth $1,224,000. SG Americas Securities LLC lifted its position in shares of Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after purchasing an additional 58,943 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after purchasing an additional 67,052 shares in the last quarter. Finally, Birchview Capital LP raised its position in Stoke Therapeutics by 147.1% during the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares in the last quarter.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $15.35 on Tuesday. The stock has a market cap of $800.06 million, a P/E ratio of -6.37 and a beta of 0.96. The firm has a 50 day moving average price of $14.23 and a 200 day moving average price of $12.74. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. The firm had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. Analysts predict that Stoke Therapeutics will post -2.18 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.